Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

44.04
+2.576.20%
Volume:1.16M
Turnover:50.31M
Market Cap:3.54B
PE:31.58
High:44.10
Open:42.01
Low:41.81
Close:41.47
52wk High:60.91
52wk Low:28.25
Shares:80.39M
Float Shares:78.97M
Volume Ratio:0.95
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.39
EPS(LYR):0.8200
ROE:8.77%
ROA:4.09%
PB:2.55
PE(LYR):53.71

Loading ...

Veracyte (VCYT) Receives a Buy from Piper Sandler

TIPRANKS
·
Aug 24

Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Aug 11

Veracyte price target lowered to $54 from $66 at Piper Sandler

TIPRANKS
·
Aug 04

Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests

Simply Wall St.
·
Aug 04

Veracyte is Maintained at Hold by Canaccord Genuity

Dow Jones
·
Aug 04

Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

TIPRANKS
·
Aug 03

Veracyte falls -24.0%

TIPRANKS
·
Jul 31

Needham Raises Price Target on Veracyte to $69 From $57, Keeps Buy Rating

MT Newswires Live
·
Jul 31

Veracyte: Strong Earnings Beat, Raised Guidance and Emerging Diagnostics Portfolio Support Durable Upside, Justifying Buy Rating

TIPRANKS
·
Jul 31

Veracyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised

MT Newswires Live
·
Jul 31

GUIDANCE: (VCYT) Veracyte Now Expects Full Year 2026 Revenue Range $590 Million - $596 Million, vs. FactSet Est of $586.4 Million

MT Newswires Live
·
Jul 31

Veracyte raises FY26 revenue view to $590M-$596M from $582M-$592M

TIPRANKS
·
Jul 31

Veracyte Q2 FY26 Swings to GAAP Net Income of $25.5 Million; Revenue Rises 15% to $150.3 Million

Reuters
·
Jul 31

Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales

Reuters
·
Jul 31

Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million

Reuters
·
Jul 31

Veracyte Q2 Adj. EPS $0.54 Beats $0.24 Estimate, Sales $150.321M Beat $144.554M Estimate

Benzinga Earnings
·
Jul 31

Veracyte Outlook 2026 - Continues to Expect Adjusted Ebitda Margin to be Greater than 26%

THOMSON REUTERS
·
Jul 31

Veracyte Q2 EPS USD 0.31

THOMSON REUTERS
·
Jul 31

Veracyte Outlook FY Revenue Growth 14-15%

THOMSON REUTERS
·
Jul 31